Small interfering RNA (siRNA)-based drugs offer a promising approach to block the synthesis of disease-causing proteins, although their delivery has posed challenges. The authors review recent advances in siRNA therapeutics, including progress in overcoming delivery challenges, and clinical trials showing efficient and durable gene knockdown in the liver.
- Anders Wittrup
- Judy Lieberman